Search results
Results from the WOW.Com Content Network
This is an accepted version of this page This is the latest accepted revision, reviewed on 27 February 2025. Class of vaccines against human papillomavirus Pharmaceutical compound HPV vaccine Vaccine description Target Human papillomavirus (HPV) Vaccine type Protein subunit Clinical data Trade names Gardasil, others AHFS / Drugs.com Monograph MedlinePlus a615028 License data US DailyMed: Human ...
Cervical cancer is the second most common female cancer among women between the ages of age of 15 to 44 years and a high prevalence rate in Ghana compared to the Western Africa region. [2] 57.8% of Ghanaian women visiting the Korle -Bu Teaching Hospital with gynecological cancer had cervical cancer as well. [3]
This is a list of countries by cancer frequency, as measured by the number of new cancer cases per 100,000 population among countries, based on the 2018 GLOBOCAN statistics and including all cancer types (some earlier statistics excluded non-melanoma skin cancer).
In most cases, the virus doesn’t cause any problems, but some infections persist and eventually lead to cancer. Across Africa, an average of 190 women died daily from cervical cancer in 2020 ...
HPV, the human papillomavirus, causes six types of cancer, including cervical cancer. Among women aged 20 to 24, cervical cancer incidence dropped by 65% from 2012 to 2019, according to a report ...
The Australian Cervical Cancer Foundation (ACCF), founded in 2008, promotes 'women's health by eliminating cervical cancer and enabling treatment for women with cervical cancer and related health issues, in Australia and in developing countries.' [174] Ian Frazer, one of the developers of the Gardasil cervical cancer vaccine, is the scientific ...
Cervical cancer was the most frequent HPV-associated cancer with on average 292 cases per year (74% of the female total, and 54% of the overall total of HPV-associated cancers). [197] A study of 996 cervical cytology samples in an Irish urban female, opportunistically screened population, found an overall HPV prevalence of 19.8%, HPV 16 at 20% ...
The cause of CIN is chronic infection of the cervix with HPV, especially infection with high-risk HPV types 16 or 18. It is thought that the high-risk HPV infections have the ability to inactivate tumor suppressor genes such as the p53 gene and the RB gene, thus allowing the infected cells to grow unchecked and accumulate successive mutations, eventually leading to cancer.